These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34601629)

  • 1. The use of oral glucocorticoids and the risk of major osteoporotic fracture in patients with myasthenia gravis.
    Safipour Z; van der Zanden R; van den Bergh J; Janssen P; Vestergaard P; de Vries F; Driessen JHM
    Osteoporos Int; 2022 Mar; 33(3):649-658. PubMed ID: 34601629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of systemic glucocorticoids and the risk of major osteoporotic fractures in patients with sarcoidosis.
    Oshagbemi OA; Driessen JHM; Pieffers A; Wouters EFM; Geusens P; Vestergaard P; van den Bergh J; Franssen FME; de Vries F
    Osteoporos Int; 2017 Oct; 28(10):2859-2866. PubMed ID: 28638981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fracture rate in patients with myasthenia gravis: the general practice research database.
    Pouwels S; de Boer A; Javaid MK; Hilton-Jones D; Verschuuren J; Cooper C; Leufkens HG; de Vries F
    Osteoporos Int; 2013 Feb; 24(2):467-76. PubMed ID: 22531999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant use of oral glucocorticoids and proton pump inhibitors and risk of osteoporotic fractures among patients with rheumatoid arthritis: a population-based cohort study.
    Abtahi S; Driessen JHM; Burden AM; Souverein PC; van den Bergh JP; van Staa TP; Boonen A; de Vries F
    Ann Rheum Dis; 2021 Apr; 80(4):423-431. PubMed ID: 33310727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.
    Amiche MA; Albaum JM; Tadrous M; Pechlivanoglou P; Lévesque LE; Adachi JD; Cadarette SM
    Osteoporos Int; 2016 May; 27(5):1709-18. PubMed ID: 26694595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Potent and Very Potent Topical Corticosteroids and the Risk of Osteoporosis and Major Osteoporotic Fractures.
    Egeberg A; Schwarz P; Harsløf T; Andersen YMF; Pottegård A; Hallas J; Thyssen JP
    JAMA Dermatol; 2021 Mar; 157(3):275-282. PubMed ID: 33471030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of high-dose intermittent systemic glucocorticoids and the risk of fracture in patients with chronic obstructive pulmonary disease.
    Oshagbemi OA; Burden AM; Shudofsky KN; Driessen JHM; Vestergaard P; Krings A; Franssen FME; van den Bergh J; de Vries F
    Bone; 2018 May; 110():238-243. PubMed ID: 29462672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of fracture in patients with myasthenia gravis: a nationwide cohort study in Korea.
    Park HS; Kim K; Yu MH; Shin HY; Rhee Y; Kim SW; Hong N
    J Bone Miner Res; 2024 Jul; 39(6):688-696. PubMed ID: 38477782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between myasthenia gravis and risk of fracture: a systematic review and meta-analysis.
    Lin CJ; Lee YS; Yeh JH; Liu SJ; Lin KY
    Osteoporos Int; 2024 Oct; 35(10):1709-1717. PubMed ID: 38748216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study.
    Amiche MA; Abtahi S; Driessen JHM; Vestergaard P; de Vries F; Cadarette SM; Burden AM
    Arch Osteoporos; 2018 Mar; 13(1):30. PubMed ID: 29552730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Higher cumulative dose of topical corticosteroids is associated with osteoporosis and major osteoporotic fracture: A nationwide case-control study.
    Hsieh BJ; Shen D; Chan TC; Cho YT; Tang CH; Chu CY
    J Eur Acad Dermatol Venereol; 2024 Jul; 38(7):1347-1356. PubMed ID: 38115791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoids Increase Fracture Risk and Fracture Prevalence Independently from Bone Mineral Density and Clinical Risk Factors: Results from the Gliwice Osteoporosis (GO) Study.
    Pluskiewicz W; Adamczyk P; Drozdzowska B
    Horm Metab Res; 2022 Jan; 54(1):20-24. PubMed ID: 34986496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fracture Risk in Patients with Myasthenia Gravis: A Population-Based Cohort Study.
    Kassardjian C; Widdifield J; Paterson JM; Kopp A; Nagamuthu C; Barnett C; Tu K; Breiner A
    J Neuromuscul Dis; 2021; 8(4):625-632. PubMed ID: 33554923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between Glucocorticoid-Induced Osteoporosis and Myasthenia Gravis: A Cross-Sectional Study.
    Konno S; Suzuki S; Masuda M; Nagane Y; Tsuda E; Murai H; Imai T; Fujioka T; Suzuki N; Utsugisawa K
    PLoS One; 2015; 10(5):e0126579. PubMed ID: 25965387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Mental Disorders and Related Medication Use With Risk for Major Osteoporotic Fractures.
    Bolton JM; Morin SN; Majumdar SR; Sareen J; Lix LM; Johansson H; Odén A; McCloskey EV; Kanis JA; Leslie WD
    JAMA Psychiatry; 2017 Jun; 74(6):641-648. PubMed ID: 28423154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway.
    Hoff M; Skurtveit S; Meyer HE; Langhammer A; Søgaard AJ; Syversen U; Skovlund E; Abrahamsen B; Forsmo S; Schei B
    Osteoporos Int; 2018 Aug; 29(8):1875-1885. PubMed ID: 29774403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.
    Van Staa TP; Laan RF; Barton IP; Cohen S; Reid DM; Cooper C
    Arthritis Rheum; 2003 Nov; 48(11):3224-9. PubMed ID: 14613287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing three machine learning approaches to design a risk assessment tool for future fractures: predicting a subsequent major osteoporotic fracture in fracture patients with osteopenia and osteoporosis.
    de Vries BCS; Hegeman JH; Nijmeijer W; Geerdink J; Seifert C; Groothuis-Oudshoorn CGM
    Osteoporos Int; 2021 Mar; 32(3):437-449. PubMed ID: 33415373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoporosis treatment considerations based upon fracture history, fracture risk assessment, vertebral fracture assessment, and bone density in Canada.
    Leslie WD; Lix LM; Binkley N
    Arch Osteoporos; 2020 Jun; 15(1):93. PubMed ID: 32577922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of objectively ascertained sibling fracture history with major osteoporotic fractures: a population-based cohort study.
    Hamad AF; Yang S; Yan L; Leslie WD; Morin SN; Walld R; Roos LL; Lix LM
    Osteoporos Int; 2021 Apr; 32(4):681-688. PubMed ID: 32935168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.